Investor Webinar Presentation
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
27 July 2023
Investor Webinar Presentation
Melbourne, Australia; 27 July 2023: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinicalstage biotechnology company specialising in cell therapeutics, is pleased to release the presentation that will be
delivered during today’s investor webinar.
The presentation provides an overview of the recently completed strategic review, as announced earlier this week (on
24 July 2023). As foreshadowed in that announcement, investors are invited to join a webcast hosted by CEO and
Managing Director, Dr Kilian Kelly at 9:15am (AEST) today (Thursday, 27 July 2023).
To pre-register for the event, please follow this link:
https://ccmediaframe.com/?id=nwqmPZoz
Upon registration, participants will receive a calendar invitation, details and a link to access the webcast.
The presentation is attached to this announcement.
-ENDSAuthorised for release by Dr Kilian Kelly, CEO & Managing Director
CONTACTS:
Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, littlebigdealconsulting@gmail.com
About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on
the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes
the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as
mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells
(MSCs), at commercial scale without the limitation of multiple donors.
Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the
treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical trial in GvHD
under a cleared US FDA IND is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot
ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology in preclinical models of
numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia, idiopathic pulmonary fibrosis,
asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.
Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry
service provider, Automic Group.
Cynata Therapeutics Limited
Level 3, 100 Cubitt Street, Cremorne, Victoria, 3121, Australia
PO Box 7165, Hawthorn North, Victoria 3122
T: +613 7067 6940 E: info@cynata.com
ABN – 98 104 037 372
A Next Generation Stem Cell
Therapeutics Company
Strategic Review Presentation
July 2023
Introduction to new CEO
“
It is a great honour and privilege to be appointed as CEO and
Managing Director of Cynata at such an exciting time in the
company's journey of developing its therapeutic stem cell
platform technology, CymerusTM.
I look forward to working with the Cynata team to drive the
successful execution of our clinical trial programs as a
number one priority. Our clinical success is underpinned by
our unique manufacturing process and highly encouraging
data across a range of clinical and pre-clinical studies.
Cynata is poised for an exciting future, with a unique
opportunity to make a significant impact on patient lives and
create long term value for shareholders. We are well funded
to advance our clinical trial program and look forward to
achieving key milestones in the coming months.
”
Dr Kilian Kelly
CEO & MD
•
Appointed as CEO / MD from 1 July 2023 onwards
– joined Cynata in 2014 as VP of Product
Development and served as COO from May 2019
to June 2023
•
Oversaw the development of CYP-001, Cynata’s
lead Cymerus product for aGvHD, navigating its
regulatory, manufacturing and clinical pathway
leading to a successful clinical trial
•
Has over two decades of biopharmaceutical R&D
experience, and previously held roles at Biota
Pharmaceuticals, Mesoblast, Kendle International,
Amgen, and AstraZeneca
•
Member of the Royal Pharmaceutical Society,
International Society for Cell and Gene Therapy
and the Australian Institute of Company Directors
2
Strategic review of product pipeline completed
Cynata has an advanced product pipeline targeting attractive market opportunities across a range of
indications
Cynata Sponsored
Target area
Acute Graft vs Host Disease (aGvHD)
Diabetic Foot Ulcers (DFU)
Partnered
Osteoarthritis (OA)
(conducted by USYD, funded by NHMRC)
Renal Transplantation (Renal)
(funded by LUMC)
Trial phase
Phase 2 ready1
Market opportunity
US$0.6bn2
Phase 1 underway
US$9.6bn3
Phase 3 underway
Phase 1 planning
US$11.6bn4
US$5.9bn5
1.Investigational New Drug approval received from the US Food and Drug Administration to commence a Phase 2 GvHD trial; 2. Global Graft versus Host Disease Market 2019-2029 (Reflects forecast market in 2026); 3. Zion
Market Research, 2019 (represents global treatment market in 2025); 4. Persistence Market Research 2018 research report: “Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)
(Reflect OA market by 2025); 5. Organ Transplant Immunosuppressant Drugs Market in 2026, Grand View Research, Inc.,2019
3
aGvHD | Phase 2 clinical trial
Cynata plans to commence recruitment during the current quarter, with results expected H2 CY 2025
aGvHD
• Acute Graft vs Host Disease (aGvHD) is a complication that can occur after
a bone marrow transplant when the donor’s immune cells (from the “graft”)
attack the recipient of the transplant (the “host”).
Key Milestones
Trial design
Completed
US IND
Achieved
Trial start-up
Underway
• European regulatory approval process ongoing
Recruitment
+ treatment
Expected Q3 CY
2023
• US and Australian centres expected to commence recruitment this quarter
Finish
recruitment
Expected Q4 CY
2024
Results
Expected H2 CY
2025
• Randomised controlled trial in ~60 patients with high risk aGvHD
Trial design
Strategic
review
Timing
• Clinical sites across in USA, Europe and Australia
• Primary objective to assess efficacy of CYP-001 in subjects by Overall
Response Rate (ORR) at Day 28
• Currently finalising trial startup activities including securing regulatory and
ethics approval – relevant approvals in Australia and the US are secured
• Patient recruitment expected to conclude by the end of CY 2024
• Primary evaluation results expected in H2 CY 2025
4
DFU | Phase 1 clinical trial
High screening failure rate has resulted in slower than expected recruitment, Cynata has undertaken steps to
accelerate recruitment rate with enrolment expected to be completed by the end of CY 2023
Diabetic Foot
Ulcers
• Diabetic Foot Ulcers (DFU) are sores on the feet of patients with diabetes
(also known as diabetic wounds)
• 30 patients with DFU will be randomly assigned to receive CYP-006TK or
standard care of treatment, over 4 weeks
Trial design
• The primary outcome measure of the trial is safety, while outcome
measures include wound healing, pain and quality of life
Key Milestones
Sign licence
with TekCyte
Completed
Ethics
approval
Completed
Trial start up
Completed
Recruitment
+ treatment
Underway
Finish
recruitment
Expected by Q4
CY 2023
Results
Expected by mid
CY 2024
• Secondary outcome measures are measured at 12 and 24 weeks
Strategic
review
• Slower than expected recruitment driven by unexpectedly high screening
failure rate as potential patients failed to meet trial eligibility criteria
• Trial protocol has been updated to address this issue, making it easier for
patients to enrol while optimising for likelihood of a positive trial outcome
• Additional centres opened taking the total number of clinical centres to four
Timing
• Patient recruitment expected to conclude in by the end of CY 2023
• Primary evaluation results expected to be released by mid CY 2024
5
OA | Phase 3 clinical trial1
Recruitment accelerating and expected to be completed by the end of CY 2023, with evaluation results
expected to be released in CY 2026
Osteoarthritis
• University of Sydney to enrol 440 patients to participate in the randomised,
double-blind placebo-controlled trial
Trial design
• Co-primary endpoints include reduction of knee pain and measure of
cartilage loss, secondary outcomes include general pain and quality of life
• Each participant receives three injections of Cymerus MSCs over a year
with a 24 months follow-up period
Strategic
review
Timing
Key Milestones
• Osteoarthritis (OA) occurs when the cartilage in a joint wears away and
can cause pain, inflammation, swelling and difficulty with movement
• Recruitment rate was initially slower than expected, largely due to the
impact of the pandemic
Initial safety
follow-up
Completed
Recruitment +
treatment
Ongoing
Finish
recruitment
Expected Q4 CY
2023 / Q1 CY 2024
Final follow-up
Expected Q4 CY
2025 / Q1 CY 2026
Results
Expected H1 CY
2026
• The recruitment rate has significantly accelerated during 2023
• Approximately 300 patients are now enrolled in the trial
(24 months)
• Patient recruitment expected to conclude in late CY 2023 / early CY 2024
• Primary evaluation results expected to be released in H1 CY 2026
1. Clinical trial entitled Stem Cells as a symptom – and strUcture-modifying Treatment for medial tibiofemoral OsteoaRthritis: a randomised placebo-controlled trial (SCUlpTOR).
6
Renal | Phase 1 clinical trial
Clinical trial start up activities with partner Leiden University Medical Center (LUMC) underway, with outcome
from regulatory approval process expected during the current quarter
Renal
Transplants
Trial design
• MSCs may reduce or eliminate the requirement for aggressive and toxic
anti-rejection drugs, leading to a substantial breakthrough in
transplantation medicine
Key Milestones
Sign contract
with LUMC
Completed
Admin
approvals
Underway
Trial start up
activities
Underway
Regulatory
approval
Expected in Q3
CY 2023
• 10 renal transplant patients will receive Cymerus MSCs after
transplantation followed by withdrawal of anti-rejection medication
• Primary endpoint is absence of graft loss after 6 months after withdrawal of
anti-rejection medication
Strategic
review
• Proposed trial design agreed between LUMC and Cynata
Timing
• Regulatory approval process underway with outcome from regulators
expected during the current quarter
• LUMC has submitted the required information package to the regulators,
and it is currently undergoing review
7
Investment Highlights
Cynata is a clinical stage biotech developing its proprietary Cymerus platform technology for the scalable
manufacture of mesenchymal stem cell (MSC) therapeutic products to treat serious disorders
Unique
Manufacturing
Strong safety
and efficacy
Single donation from a
single donor
iPSC strategy
overcomes
suboptimalities in
conventional MSC
manufacturing
Positive pre-clinical
and clinical data
supporting versatility and
efficacy of Cynata’s
MSCs; all endpoints met
in aGvHD phase 1 with
ORR of 87%
1. Current expectation
2. Cash as at 30 June 2023
Multiple
clinical trials
Large
addressable
market
Rich clinical pipeline:
•
aGvHD (phase 2)
•
DFU (phase 1)
•
Osteoarthritis (phase 3)
•
Renal (phase 1)
Combined market
opportunity of clinical
trials underway and in
planning is ~A$38bn
Fully funded
Fully funded to complete
planned clinical trials
with ~A$16m2 in cash
OA and renal trials fully
funded by external
partners
8
Important information
Summary information
This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries
(CYP) which is current as at 26 July 2023. This Presentation should be read in conjunction with CYP’s other
periodic and continuous disclosure information lodged with the Australian Securities Exchange (ASX), which
are available at www.asx.com.au.
Not an offer
This Presentation is not a prospectus, product disclosure statement or other offering document under
Australian law (and will not be lodged with the ASIC) or any other law. This Presentation is for information
purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any
jurisdiction. The release, publication or distribution of this Presentation (including an electronic copy) outside
Australia may be restricted by law. If you come into possession of this Presentation, you should observe such
restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.
Not investment advice
This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal
advice) or any recommendation by CYP or its advisers to acquire CYP securities. This Presentation has been
prepared without taking account of any person’s individual investment objectives, financial situation or
particular needs. Before making an investment decision, prospective investors should consider the
appropriateness of the information having regard to their own investment objectives, financial situation and
needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. CYP is not licensed to
provide financial product advice in respect of CYP securities.
Investment risk and past performance
An investment in CYP securities is subject to known and unknown risks, some of which are beyond the
control of CYP and its directors. CYP does not guarantee any particular rate of return or performance of CYP.
Past performance cannot be relied upon as an indicator of (and provides no guidance as to) future CYP
performance including future share price performance.
‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’, ‘guidance’, ‘potential’ and other similar
expressions. The forward looking statements contained in this Presentation are not guarantees or predictions
of future performance and involve known and unknown risks and uncertainties and other factors, many of
which are beyond the control of CYP, its directors and management, and may involve significant elements of
subjective judgment and assumptions as to future events which may or may not be correct. There can be no
assurance that actual outcomes will not differ materially from these forward looking statements. A number of
important factors could cause actual results or performance to differ materially from the forward looking
statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of
achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future
matters contained in this Presentation. The forward looking statements are based on information available to
CYP as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing
Rules), CYP and its directors, officers, employees, advisers, agents and intermediaries undertake no
obligation to provide any additional or updated information whether as a result of new information, future
events or results or otherwise. You are strongly cautioned not to place undue reliance on forward-looking
statements, particularly in light of the current economic climate and the significant volatility, uncertainty and
disruption caused by the outbreak of COVID-19.
Industry and Market data
Certain market and industry data used in connection with this Presentation may have been obtained from
research, surveys or studies conducted by third parties, including industry or general publications. Neither
CYP nor its representatives have independently verified any such market or industry data provided by third
parties or industry or general publications.
Disclaimer
To the maximum extent permitted by law, CYP and its advisers, affiliates, related bodies corporate, directors,
officers, partners, employees and agents (Related Persons) exclude and disclaim all liability, including
without limitation for negligence, for any expenses, losses, damages or costs arising from this Presentation or
reliance on anything contained in or omitted from it. To the maximum extent permitted by law, CYP and its
Related Persons make no representation or warranty, express or implied, as to the currency, accuracy,
reliability or completeness of information in this Presentation and disclaim any obligation or undertaking to
release any update or revision to the information in this Presentation to reflect any change in expectations or
assumptions.
Financial data
All financial information in this Presentation is in Australian currency (A$) unless otherwise stated.
This Presentation contains historical financial information based on the Company’s results for the quarter
year to June 2023. This information is disclosed in the 4C report lodged with ASX on 26 July 2022. Any
Statements made in this Presentation are made only as at the date of this Presentation. The information in
discrepancies between totals and sums of components in tables and figures in this Presentation are due to this Presentation remains subject to change without notice.
rounding.
Forward-looking statements
This Presentation contains certain ‘forward looking statements’, which can generally be identified by the use
of forward looking words such as ‘expect’, ‘anticipate’, ‘likely’, ‘intend’, ‘should’, ‘could’, ‘may’, ‘predict’, ‘plan’,
9
Contact Us
Cynata Therapeutics Limited
Level 3
100 Cubitt Street
Cremorne
Victoria 3121
Australia
Contact details:
kilian.kelly@cynata.com
www.cynata.com
Share your feedback
Discover